【券商聚焦】西部证券首予维立志博-B“买入”评级 指公司核心产品临床数据亮眼

金吾财讯
Feb 20

(原标题:【券商聚焦】西部证券首予维立志博-B(09887)“买入”评级 指公司核心产品临床数据亮眼)金吾财讯|西部证券发布研报指,维立志博-B(09887.HK)核心产品LBL-024(PD-L1/4-1BB双抗)在肺外神经内分泌癌(EP-NEC)临床数据优异,单药治疗3L+ EP-NEC ORR达33.3%,计划2026Q3递交BLA;LBL-034(GPRC5D/CD3双抗)在复发难治多发性...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10